GCTK

3.97% -0.031

시장 영업 전: .75 0.001 +0.13%

Glucotrack Inc (GCTK)

개요 뉴스 가격 이력 Financials 토론 예측 주식 분할

Relative Volume:

Glucotrack Inc Stock (GCTK) Company Profile

Glucotrack Inc

Healthcare (1113)

972 (8) 675-7878

301 RT 17 NORTH, RUTHERFORD

최신 SEC 제출 서류

GCTK's Discussions on Twitter

Compare GCTK vs ISRG, BDX, MDLN, ALC, RMD

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
GCTK Glucotrack Inc	0.749	1.52M	0	-19.39M	-15.34M	-18.91
ISRG Intuitive Surgical Inc	451.29	165.37B	10.06B	2.88B	2.49B	7.876
BDX Becton Dickinson Co	156.69	45.13B	21.92B	1.76B	2.63B	6.1223
MDLN Medline Inc	47.51	39.17B	28.43B	1.16B	1.26B	1.4457
ALC Alcon Inc	77.82	39.14B	10.40B	980.00M	1.61B	1.9749
RMD Resmed Inc	221.22	32.94B	5.40B	1.49B	1.78B	10.12

Glucotrack Inc 주식(GCTK)의 최신 뉴스

Glucotrack Inc (GCTK) 재무 분석

Glucotrack Inc (GCTK)

Glucotrack Inc Stock (GCTK) Company Profile

Compare GCTK vs ISRG, BDX, MDLN, ALC, RMD

Glucotrack Inc 주식(GCTK)의 최신 뉴스

Study Supports GlucoTrack’s Blood Glucose Monitoring Implant - Yahoo Finance

Glucotrack publishes peer-reviewed study on glucose sensor stability - Investing.com

Glucotrack publishes peer-reviewed study on glucose sensor stability By Investing.com - Investing.com Canada

Glucotrack Announces Publication of Peer-Reviewed Study Supporting Long-Life Sensor Design for Implantable Continuous Blood Glucose Monitoring Technology - marketscreener.com

One-year lab test backs Glucotrack implantable glucose monitor - Stock Titan

GCTK | GlucoTrack, Inc. Common Stock Insider Trading - Quiver Quantitative

GlucoTrack Executes Debt-for-Equity Exchange to Reduce Obligations - TipRanks

Glucotrack exchanges $600,000 note for 895,000 shares with investor By Investing.com - Investing.com

Glucotrack Swaps $600,000 Note Portion for 895,000 Shares Under Exchange Agreement - TradingView

Glucotrack (NASDAQ: GCTK) swaps $600K debt for 895,000 shares - Stock Titan

GlucoTrack stock gains as data backs FDA filing plans for glucose monitoring tech - MSN

Technical Analysis: Is GlucoTrack Inc impacted by rising ratesProduct Launch & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn

$Glucotrack (GCTK.US)$ thanks market - Moomoo

RSI Check: Will GlucoTrack Inc benefit from geopolitical trends2026 Intraday Action & Weekly High Return Stock Forecasts - baoquankhu1.vn

GCTK Stock Price, Quote & Chart | GLUCOTRACK INC (NASDAQ:GCTK) - ChartMill

Glucotrack reports net loss of USD 19.4M in FY 2025 - Medical Buyer

Glucotrack, Inc. 2025 Annual Report – Implantable Continuous Blood Glucose Monitor Development, Regulatory Progress, and Risk Factors 66 - Minichart

Glucotrack FY25 Net Loss Narrows; Plans To Submit An IDE For CBGM In Q2 2026 - RTTNews

GCTK: Improved net loss and cash position support 2026 clinical trial launch for implantable CBGM - TradingView — Track All Markets

Glucotrack (GCTK) advances implantable CBGM but flags going concern risk - Stock Titan

GlucoTrack, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com

Glucotrack (NASDAQ: GCTK) trims 2025 loss and readies IDE for implantable CBGM trials - Stock Titan

Glucotrack, Inc. Announces IDE Filing Plans for Continuous Blood Glucose Monitoring Technology and Patents Issued by USPTO - Quiver Quantitative

Glucotrack’s 3-year glucose implant targets a U.S. human trial in 2026 - Stock Titan

GCTK stock is soaring pre-market today — what is fueling the surge? - MSN

Technical Analysis: What analysts say about GlucoTrack Inc stock2026 Analyst Calls & Low Drawdown Trading Techniques - baoquankhu1.vn

GlucoTrack Plummets 27%: Is This the Bottom of a Deep Downtrend? A High-Stakes Analysis for 2026 - Bitget

GCTK PE Ratio & Valuation, Is GCTK Overvalued - Intellectia AI

GlucoTrack Prepares FDA Submission for Implantable CBGM Trial - The Globe and Mail

Glucotrack plans FDA submission for implantable glucose monitor By Investing.com - Investing.com Australia

Glucotrack to File for FDA Exemption Based on 2025 Milestones - Yahoo Finance

GCTK Stock Is Soaring Today — What Is Fueling The Surge? - Stocktwits

Glucotrack to Submit IDE Application to FDA in Early Q2 - citybiz

Glucotrack, Inc. (GCTK) Stock: Prepares FDA Submission as Clinical Data Shows Strong Accuracy - parameter.io

Glucotrack plans US trial of implantable glucose monitor this year - MedTech Dive

Microcap MedTech Moving on U.S. Clinical Milestone - The Globe and Mail

GCTK stock GlucoTrack NASDAQ +29.80% on FDA IDE plan 27 Mar 2026: Earnings in focus - Meyka

Latest Developments Propel GCTK Stock with Breakthrough Acquisitions - StocksToTrade

Why Is GlucoTrack Stock Soaring Friday?GlucoTrack (NASDAQ:GCTK) - Benzinga

GlucoTrack (GCTK) Surges 45% in Afternoon Trading—What's Fueling This Unusual Move? - Bitget

Glucotrack Inc Files Significant Ide with Fda for Us Clinical Trial in Early Second Quarter Based on Critical 2025 Milestones - marketscreener.com

Glucotrack plans FDA submission for implantable glucose monitor - investing.com

Glucotrack to file IDE with FDA in Q2 2026 after successful human trials and new patents - TradingView

GCTK Stock Is Soaring Pre-Market Today — What Is Fueling The Surge? - Stocktwits

Glucotrack (NASDAQ: GCTK) advances implantable CBGM with IDE plan and new patents - Stock Titan

Glucotrack to file significant IDE with FDA for US clinical trial in early Q2 based on critical 2025 milestones - MarketScreener

Glucotrack Plans IDE Submission to FDA in Early Q2 2026 for Non-Invasive Glucose Monitoring Clinical Trials - geneonline.com

Glucotrack to File Significant IDE with FDA for US Clinical Trial in Early Q2 Based on Critical 2025 Milestones - marketscreener.com

Is GlucoTrack Inc. a stock for growth or value investorsWeekly Market Outlook & Weekly Top Stock Performers List - baoquankhu1.vn

Sentiment Review: What analysts say about GlucoTrack Inc stockOptions Play & Precise Entry and Exit Recommendations - baoquankhu1.vn

Growth Recap: Is GlucoTrack Inc backed by strong institutional buying2026 Closing Moves & Short-Term High Return Ideas - baoquankhu1.vn

Glucotrack Inc (GCTK) 재무 분석

매출

순이익

현금흐름

주당 순 이익

GCTK과 유사한 종목